BRPI0818837A2 - Composto de alfa-(n-sulfonamido) acetamida como um inibidor de produção de peptídeo beta amiloide - Google Patents

Composto de alfa-(n-sulfonamido) acetamida como um inibidor de produção de peptídeo beta amiloide

Info

Publication number
BRPI0818837A2
BRPI0818837A2 BRPI0818837A BRPI0818837A2 BR PI0818837 A2 BRPI0818837 A2 BR PI0818837A2 BR PI0818837 A BRPI0818837 A BR PI0818837A BR PI0818837 A2 BRPI0818837 A2 BR PI0818837A2
Authority
BR
Brazil
Prior art keywords
sulfonamido
inhibitor
alpha
amyloid peptide
beta amyloid
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
John E Starrett
Jr.
Kevin W Gillman
Richard E Olson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40193955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0818837(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0818837A2 publication Critical patent/BRPI0818837A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0818837 2007-10-31 2008-10-14 Composto de alfa-(n-sulfonamido) acetamida como um inibidor de produção de peptídeo beta amiloide BRPI0818837A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98411807P 2007-10-31 2007-10-31
PCT/US2008/079798 WO2009058552A1 (en) 2007-10-31 2008-10-14 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Publications (1)

Publication Number Publication Date
BRPI0818837A2 true BRPI0818837A2 (pt) 2015-04-22

Family

ID=40193955

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818837 BRPI0818837A2 (pt) 2007-10-31 2008-10-14 Composto de alfa-(n-sulfonamido) acetamida como um inibidor de produção de peptídeo beta amiloide

Country Status (28)

Country Link
US (2) US8084477B2 (enExample)
EP (3) EP2295417B1 (enExample)
JP (1) JP5460605B2 (enExample)
KR (1) KR20100075575A (enExample)
CN (2) CN102718689A (enExample)
AR (1) AR069135A1 (enExample)
AT (1) ATE502022T1 (enExample)
AU (1) AU2008319122A1 (enExample)
BR (1) BRPI0818837A2 (enExample)
CA (1) CA2704360A1 (enExample)
CL (1) CL2008003271A1 (enExample)
CO (1) CO6270332A2 (enExample)
CY (2) CY1112337T1 (enExample)
DE (1) DE602008005636D1 (enExample)
DK (2) DK2205575T3 (enExample)
EA (2) EA201171439A1 (enExample)
ES (2) ES2361283T3 (enExample)
HR (2) HRP20110219T1 (enExample)
IL (1) IL205406A0 (enExample)
MX (1) MX2010004319A (enExample)
NZ (1) NZ584545A (enExample)
PE (1) PE20091394A1 (enExample)
PL (2) PL2295417T3 (enExample)
PT (2) PT2295417E (enExample)
SG (2) SG174043A1 (enExample)
SI (2) SI2205575T1 (enExample)
TW (1) TW200927099A (enExample)
WO (1) WO2009058552A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE430727T1 (de) 2001-12-20 2009-05-15 Bristol Myers Squibb Co Alpha-(n-sulfonamid)acetamidderivate als beta- amyloidinhibitoren
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
MX2011009271A (es) * 2009-03-19 2011-09-26 Bristol Myers Squibb Co Nuevo compuesto de alfa-(n-sulfonamido)acetamida como inhibidor de la produccion del peptido beta amiloide.
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
CN104072408B (zh) * 2010-03-12 2016-09-14 日本曹达株式会社 含有吡啶环的化合物、及卤代甲基吡啶衍生物以及四唑基肟衍生物的制造方法
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
EP2643299B1 (en) * 2010-11-22 2016-06-22 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
JP2015529250A (ja) 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company フルオロアルキルジベンゾジアゼピノン化合物
CN104797584A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 作为notch抑制剂的三环杂环化合物
CN104822677A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 氟烷基-1,4-苯并二氮杂*酮化合物
WO2014047369A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
CN103058913B (zh) * 2012-12-13 2015-09-30 江苏弘和药物研发有限公司 5-氯异吲哚酮的合成方法
CN104163784B (zh) * 2014-06-20 2019-01-08 湖南天地恒一制药有限公司 一种奥拉西坦的合成工艺
RU2757276C2 (ru) 2016-12-16 2021-10-12 Пайплайн Терапьютикс, Инк. Способы лечения кохлеарной синаптопатии
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN107935957B (zh) * 2017-12-02 2020-08-21 江苏仁明生物科技有限公司 一种合成高纯度沙坦侧链ttbb的方法
MX2020012495A (es) 2018-06-01 2021-02-15 Novartis Ag Moleculas de union contra bcma y usos de las mismas.
CN108640886A (zh) * 2018-08-01 2018-10-12 余锋 一种作为β-淀粉样肽产生的抑制剂BMS-708163的合成方法
TW202115114A (zh) 2019-06-24 2021-04-16 瑞士商諾華公司 針對靶向b細胞成熟抗原的多特異抗體之給藥方案及組合療法
CN113466367B (zh) * 2021-06-25 2023-04-14 深圳万乐药业有限公司 乌苯美司原料药中α-苯乙胺杂质检测方法
CN113816874B (zh) * 2021-10-30 2024-01-26 大连双硼医药化工有限公司 一种合成4-氰基-2-氟苄醇的工艺方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
PL326700A1 (en) 1995-11-17 1998-10-26 Warner Lambert Co Sulphonamide-based inhibitors of intercellular substance metaloproteinases
RU2202540C2 (ru) 1996-07-22 2003-04-20 Монсанто Компани Тиолсульфонамидные ингибиторы металлопротеазы
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するTNF―α産生抑制剤
NZ512306A (en) 1999-01-27 2003-10-31 American Cyanamid Co Acetylenic sulfonamide thiol tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
EP1159263A1 (en) * 1999-02-26 2001-12-05 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
US6541467B1 (en) * 2000-04-14 2003-04-01 Corvas International, Inc. Thrombin inhibitors having a lactam at P3
US20020115640A1 (en) * 2000-11-30 2002-08-22 Claiborne Akiyo K. Farnesyltransferase inhibitors
US20040179277A1 (en) * 2001-12-14 2004-09-16 Stallard Charles R Precisely aligned lens structure and a method for its fabrication
ATE430727T1 (de) 2001-12-20 2009-05-15 Bristol Myers Squibb Co Alpha-(n-sulfonamid)acetamidderivate als beta- amyloidinhibitoren
PL372090A1 (en) * 2002-02-28 2005-07-11 Astrazeneca Ab Chemical compounds
ES2286345T3 (es) * 2003-03-20 2007-12-01 Santhera Pharmaceuticals (Schweiz) Ag Derivados de piperidina y piperazina substituidos como moduladores del receptor de melanocortina-4.
JP2006522126A (ja) 2003-03-31 2006-09-28 ワイス βアミロイド生産のフルオロ含有およびトリフルオロアルキル含有複素環スルホンアミド阻害物質およびその誘導体
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
BRPI0707742A2 (pt) 2006-02-17 2011-05-10 Wyeth Corp processo para preparar um composto
US7687666B2 (en) 2006-02-17 2010-03-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
WO2008112249A1 (en) 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production

Also Published As

Publication number Publication date
EP2295417B1 (en) 2012-07-04
US8350084B2 (en) 2013-01-08
CY1113346T1 (el) 2016-06-22
CN101910141B (zh) 2012-12-19
EP2205575B1 (en) 2011-03-16
JP5460605B2 (ja) 2014-04-02
CY1112337T1 (el) 2015-12-09
PT2205575E (pt) 2011-05-23
EA016447B1 (ru) 2012-05-30
SG174044A1 (en) 2011-09-29
EA201171439A1 (ru) 2012-05-30
CN102718689A (zh) 2012-10-10
CN101910141A (zh) 2010-12-08
CL2008003271A1 (es) 2009-07-10
EP2471769A1 (en) 2012-07-04
PL2295417T3 (pl) 2012-11-30
SI2205575T1 (sl) 2011-07-29
US20120088925A1 (en) 2012-04-12
IL205406A0 (en) 2010-12-30
DK2295417T3 (da) 2012-10-15
AU2008319122A1 (en) 2009-05-07
EA201000714A1 (ru) 2010-10-29
CA2704360A1 (en) 2009-05-07
DE602008005636D1 (de) 2011-04-28
ATE502022T1 (de) 2011-04-15
HRP20120703T1 (hr) 2012-09-30
TW200927099A (en) 2009-07-01
JP2011502153A (ja) 2011-01-20
KR20100075575A (ko) 2010-07-02
ES2390042T3 (es) 2012-11-06
MX2010004319A (es) 2010-04-30
HK1141801A1 (en) 2010-11-19
SI2295417T1 (sl) 2012-11-30
EP2205575A1 (en) 2010-07-14
PT2295417E (pt) 2012-09-26
CO6270332A2 (es) 2011-04-20
WO2009058552A1 (en) 2009-05-07
SG174043A1 (en) 2011-09-29
PE20091394A1 (es) 2009-09-25
HRP20110219T1 (hr) 2011-04-30
EP2295417A1 (en) 2011-03-16
ES2361283T3 (es) 2011-06-15
HK1155161A1 (en) 2012-05-11
US20090111858A1 (en) 2009-04-30
NZ584545A (en) 2011-04-29
PL2205575T3 (pl) 2011-09-30
AR069135A1 (es) 2009-12-30
US8084477B2 (en) 2011-12-27
DK2205575T3 (da) 2011-07-11

Similar Documents

Publication Publication Date Title
BRPI0818837A2 (pt) Composto de alfa-(n-sulfonamido) acetamida como um inibidor de produção de peptídeo beta amiloide
EP2299999A4 (en) STAT3 INHIBITORS
EP2272817A4 (en) PAI-1 INHIBITORS
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
SMT201700068B (it) Inibitori cristallini del tripeptide epossichetone proteasi
FR2927222B1 (fr) Arrangement de rack avionique
SMT201600291B (it) Inibitori di proteasi hcv
SMT201600075B (it) Composto di diamminocarbossammide eterociclica
EP2424873A4 (en) NOVEL GALECTIN GALACTOSIDHEMMER
EP2485589A4 (en) HETEROARYL-BTK INHIBITORS
LT3403654T (lt) Geriamosios kortikosteroido kompozicijos
DK2419429T3 (da) Imidazopyraziner som inhibitorer af proteinkinaser
BR112012006686A2 (pt) composto amida substituído
EP2192838A4 (en) HETEROCYCLIC NEKROPTOSIS HEMMER
DK2262793T3 (da) Krystallinske former af nilotinib-hci
BRPI0922804A8 (pt) formas de dosagem sólidas de bendamustina
EP2139883A4 (en) HIV-1 protease inhibitor
BRPI0915032A2 (pt) hidrogenação de alcanos multi-bromados
EP2201946A4 (en) HAMMER OF PAI-1 PRODUCTION
BRPI0820677A2 (pt) Misturas de compostos pesticidas
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
EP2349335A4 (en) LEVETIRACETAM IMMUNOASSAYS
EP2413941A4 (en) Renin Inhibitors
BRPI0813830A2 (pt) Purificação de polipeptídeos peguilados
SMT201600031B (it) Composti eterociclici di fenossimetile

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]